Physician profile
Mitchell R Halter
NPI 1841287398
$4,892.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $951 · 2021: $745 · 2022: $823 · 2023: $941 · 2024: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.95 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $654.51 | 2019-2024 | Ajovy |
| Allergan, INC. | $650.48 | 2019-2021 | |
| Lilly USA, LLC | $407.30 | 2019-2024 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $381.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $365.17 | 2021 | |
| Lundbeck LLC | $328.11 | 2020-2024 | Vyepti |
| Amgen INC. | $268.04 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $177.56 | 2022 | |
| Idorsia Pharmaceuticals US INC | $172.64 | 2023 | Quviviq |
| Pfizer INC. | $137.97 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $106.54 | 2023-2024 | Xeomin, Inbrija |
| Upsher-Smith Laboratories LLC | $73.93 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $44.81 | 2023 | Lyvispah |
| Vanda Pharmaceuticals INC. | $35.69 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $19.01 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.74 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.39 | 2022 | |
| Currax Pharmaceuticals LLC | $13.42 | 2022 | |
| Metacel Pharmaceuticals LLC | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Halter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.